Company: GANX
Filing Date: 2025-05-28
Form Type: S-3
Source: 0001104659-25-053619
Chunk: 5

Company: Gain Therapeutics, Inc.
Filing Date: 2025-05-28
Form: S-3
Chunk 5
---
 21 | ​ | ​ |
| ​ | DESCRIPTION OF UNITS                                 | ​ | ​ | ​ | ​ | 22 | ​ | ​ |
| ​ | FORMS OF SECURITIES                                  | ​ | ​ | ​ | ​ | 23 | ​ | ​ |
| ​ | PLAN OF DISTRIBUTION                                 | ​ | ​ | ​ | ​ | 25 | ​ | ​ |
| ​ | LEGAL MATTERS                                        | ​ | ​ | ​ | ​ | 29 | ​ | ​ |
| ​ | EXPERTS                                              | ​ | ​ | ​ | ​ | 29 | ​ | ​ |
| ​ | ADDITIONAL INFORMATION                               | ​ | ​ | ​ | ​ | 30 | ​ | ​ |
| ​ | INCORPORATION OF CERTAIN INFORMATION BY REFERENCE    | ​ | ​ | ​ | ​ | 31 | ​ | ​ |

i

TABLE OF CONTENTS

### ABOUT THIS PROSPECTUS
This prospectus is part of a registration statement that we filed with the Securities and Exchange Commission, or SEC, using a “shelf” registration process. Under this shelf registration process, we may from time to time offer and sell, in one or more offerings, any or all of the securities described in this prospectus, separately or together, up to an aggregate offering price of $100,000,000. This prospectus provides you with a general description of the securities we may offer. When we issue securities pursuant to this prospectus, we will provide a prospectus supplement that will contain specific information about the terms of that offering. The prospectus supplement may also add, update or change information contained in this prospectus. You should read both this prospectus and any prospectus supplement together with additional information described under the heading “Additional Information” and “Incorporation of Certain Information by Reference.”

Gain Therapeutics, Inc. is referred to herein as “Gain,” “the Company,” “we,” “us,” and “our,” unless the context indicates otherwise.

You may only rely on the information contained in or incorporated by reference in this prospectus, and any accompanying prospectus supplement or in any free writing prospectus prepared by or on behalf of us or to which we have referred you. We have not authorized anyone to provide you with different information. This prospectus and any prospectus supplement do not constitute an offer to sell or a solicitation of an offer to buy any securities other than the securities offered by this prospectus or such accompanying prospectus supplement.